Progress of gut microbiome and its metabolomics in early screening of colorectal cancer

• Lujia Zhou ^[1] ; Zhengting Jiang ^[1] ; Zhilin Zhang ^[1] ; Juan Xing ^[1] ; Daorong Wang ^[2] ; Dong Tang ^[2]
  1. [1] Clinical Medical College, Yangzhou University, Yangzhou, Jiangsu Province, 225000, People’s Republic of China
  2. [2] Department of General Surgery, Institute of General Surgery, Northern Jiangsu People’s Hospital, Clinical Medical College, Yangzhou University, Yangzhou, 225000, People’s Republic of China
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 25, Nº. 7 (July), 2023, págs. 1949-1962
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Gut microbes are widely considered to be closely associated with colorectal cancer (CRC) development. The microbiota is regarded as a potential identifier of CRC, as several studies have found great significant changes in CRC patients' microbiota and metabolic groups. Changes in microbiota, like Fusobacterium nucleatum and Bacteroides fragilis, also alter the metabolic activity of the host, promoting CRC development. In contrast, the metabolome is an intuitive discriminative biomarker as a small molecular bridge to distinguish CRC from healthy individuals due to the direct action of microbes on the host. More diagnostic microbial markers have been found, and the potential discriminatory power of microorganisms in CRC has been investigated through the combined use of biomic genomic metabolomics, bringing new ideas for screening fecal microbial markers. In this paper, we discuss the potential of microorganisms and their metabolites as biomarkers in CRC screening, hoping to provide thoughts and references for non-invasive screening of CRC.